Beyond its angiogenic role, VEGFR2 contributes directly to gastric cancer tumorigenesis: overexpression in tumor cells promotes proliferation, migratory capacity, and xenograft tumor growth, in part through upregulation of vitronectin (VTN), a factor associated with adverse clinical outcomes [38]. The gene discussed is VTN; the disease is neoplasm.